exosom
small
membran
vesicl
secret
cell
type
vesicl
particip
commun
content
consist
rna
lipid
protein
protein
ie
ubiquit
express
depend
cell
sourc
cell
typespecif
protein
found
respons
function
protein
lipid
rna
express
exosom
differ
cell
organ
extens
describ
exocarta
databas
exosom
easili
isol
ultracentrifug
vitro
cultur
cell
differ
isol
protocol
describ
literatur
protocol
differ
basi
particular
type
research
divid
procedur
discoveri
diagnost
prepar
research
clinicalgrad
product
exosom
safe
technolog
larg
scale
product
absolut
prerequisit
preclin
set
especi
murin
model
exosom
appli
treatment
mani
differ
diseas
infect
allergi
well
autoimmun
diseas
regard
immunomodulatori
potenti
vesicl
first
vivo
studi
conduct
et
al
use
bone
marrow
dendrit
cellderiv
exosom
compar
preclin
studi
clinic
trial
conduct
use
exosom
first
clinic
trial
conduct
cancer
patient
use
dendrit
cellderiv
exosom
ascitesderiv
exosom
safeti
toler
efficaci
treatment
demonstr
present
therapeut
potenti
exosom
deriv
msc
exomsc
success
appli
murin
model
treatment
cardiovascular
diseas
sens
proangiogen
effect
describ
differ
stem
cell
subset
may
respons
therapeut
effect
differ
term
morpholog
featur
isol
storag
condit
exosom
deriv
msc
sourc
identif
exomsc
express
common
surfac
marker
exosom
also
adhes
molecul
includ
express
membran
msc
accumul
evid
establish
effect
msc
transplant
thought
mediat
part
paracrin
effect
inde
context
myocardi
infarct
experiment
quantifi
overal
benefici
effect
paracrin
mechan
account
sever
advantag
use
releas
factor
msc
describ
exampl
transfer
cell
may
die
fulli
home
site
damag
tissu
wherea
biolog
factor
local
administ
control
dosag
current
preclin
trial
exomsc
driven
repair
damag
tissu
report
focus
immunomodulatori
effect
vesicl
hypothes
exomsc
may
similar
regulatori
function
origin
msc
sourc
differenti
activ
function
differ
cell
subset
support
idea
previou
report
demonstr
immunomodulatori
capac
msc
nk
cell
cytotox
lymphocyt
cell
dendrit
cell
invari
nkt
cell
mediat
paracrin
mechan
order
address
hypothesi
vitro
experi
perform
character
immunomodulatori
effect
exomsc
vitro
stimul
cell
phenotyp
character
cytotox
helper
cell
activ
differenti
marker
togeth
function
assay
prolifer
product
demonstr
exomsc
exert
inhibitori
effect
differenti
activ
cell
well
reduc
prolifer
releas
vitro
expand
cell
summari
result
suggest
exomsc
cellderiv
product
could
consid
immunomodulatori
therapeut
agent
treatment
immunolog
diseas
human
adipos
mesenchym
stem
cell
hasc
isol
lipoaspir
obtain
human
adipos
tissu
healthi
adult
donor
lipoaspir
wash
pb
digest
collagenas
type
pb
digest
sampl
wash
fetal
bovin
serum
fb
treat
ammonium
chlorid
mm
suspend
cultur
medium
dmem
contain
fb
filter
nylon
mesh
cell
seed
onto
tissu
cultur
flask
expand
chang
cultur
medium
everi
day
cell
pass
new
cultur
flask
cultur
reach
confluenc
addit
hasc
test
flow
cytometri
use
specif
surfac
marker
neg
posit
data
shown
cell
line
two
healthi
donor
use
studi
biolog
sampl
obtain
inform
consent
auspic
appropri
research
ethic
committe
enrich
fraction
exosom
hasc
exohasc
obtain
hasc
cultur
flask
cell
reach
confluenc
cultur
medium
dmem
contain
fb
replac
exosom
isol
medium
dmem
contain
hasc
supernat
collect
everi
day
exosom
isol
supernat
two
success
centrifug
g
min
g
min
elimin
cell
debri
follow
ultracentrifug
g
h
precipit
exosom
pellet
resuspend
pb
store
prior
vitro
experi
exosom
quantifi
bradford
assay
character
nanoparticl
track
analysi
concentr
size
purifi
exosom
measur
nanoparticl
track
analysi
nanosight
ltd
amesburi
uk
relat
rate
brownian
motion
particl
size
result
analyz
use
nanoparticl
track
analysi
softwar
packag
version
triplic
sampl
dilut
sterilefilt
pb
analyz
exosom
concentr
indirectli
measur
protein
quantif
bradford
assay
quantifi
protein
concentr
exosom
sampl
incub
bradford
reagent
bio
rad
laboratori
hercul
ca
rt
absorb
read
min
nm
protein
concentr
extrapol
standard
concentr
curv
bovin
serum
albumin
peripher
blood
lymphocyt
pbl
healthi
donor
obtain
centrifug
sigma
st
loui
mo
usa
wash
twice
pb
pbl
frozen
store
liquid
nitrogen
vitro
experi
cell
aliquot
thaw
ad
ml
rpmi
centrifug
rpm
min
elimin
dmso
pellet
resuspend
rpmi
supplement
fb
determin
immunomodulatori
effect
exohasc
vitro
stimul
pbl
purifi
pbl
seed
well
plate
per
well
stimul
pbl
cell
activationexpans
kit
miltenyi
biotec
inc
san
diego
ca
usa
use
ad
microbead
coat
well
final
exosom
differ
concentr
pbl
ad
well
pbl
cultur
day
neg
control
nonstimul
pbl
posit
control
stimul
pbl
without
exosom
use
experi
prolif
behavior
cell
quantifi
carboxyfluorescein
succinimidyl
ester
cfse
dilut
cfse
stain
perform
seed
use
cfse
cell
prolifer
kit
invitrogen
eugen
final
concentr
min
follow
immedi
quench
cultur
medium
day
vitro
stimul
pbl
presenc
absenc
exohasc
test
cfse
dilut
flow
cytometri
flow
cytometr
analysi
vitro
stimul
pbl
cell
collect
well
day
pipet
cell
stain
fluorescencelabel
human
monoclon
antibodi
bd
bioscienc
san
jose
ca
usa
marker
express
analysi
perform
follow
cell
incub
min
appropri
concentr
monoclon
antibodi
presenc
pb
contain
fb
cell
wash
resuspend
pb
flow
cytometr
analysi
perform
facscalibur
cytomet
bd
bioscienc
san
jose
ca
usa
acquisit
event
cell
primarili
select
use
forward
side
scatter
characterist
fluoresc
analyz
use
cellquest
softwar
bd
bioscienc
san
jose
ca
usa
isotypematch
neg
control
antibodi
use
experi
mean
rel
fluoresc
intens
calcul
divid
mean
fluoresc
intens
mfi
mfi
neg
control
assay
pbl
vitro
stimul
cell
activationexpans
kit
miltenyi
biotec
inc
san
diego
ca
usa
day
presenc
exohasc
pbl
pbl
incub
h
bd
golgistop
pbl
stain
percplabel
apclabel
fix
permeabil
use
bd
cytofixcytoperm
fixationpermeabil
kit
final
cell
stain
pelabel
antibodi
reagent
bd
bioscienc
san
jose
ca
usa
analysi
flow
cytometri
perform
measur
frequenc
express
gate
cell
data
statist
analyz
use
student
ttest
variabl
parametr
distribut
prolifer
assay
anova
post
hoc
bonferroni
test
perform
pvalu
consid
statist
signific
statist
determin
made
use
softwar
spss
chicago
il
usa
enrich
fraction
exosom
collect
hasc
ultracentrifug
protein
concentr
exosom
determin
bradford
assay
three
independ
perform
nanoparticl
track
analysi
perform
exosom
sampl
quantifi
size
distribut
particl
concentr
firstli
total
protein
concentr
allow
us
quantifi
exosom
vitro
assay
secondli
nanoparticl
track
analysi
allow
us
character
releas
vesicl
size
isol
vesicl
rang
nm
mean
size
standard
deviat
nm
repres
result
exohasc
display
frequenc
size
distribut
graph
figur
correspond
nanoparticl
track
analysi
video
frame
includ
video
supplementari
materi
final
concentr
exosom
n
determin
nanoparticl
track
analysi
rang
particl
per
millilit
mean
concentr
particl
per
millilit
order
assess
biolog
activ
exohasc
aim
determin
effect
prolifer
rate
lymphocyt
subset
total
pbl
stimul
describ
section
materi
method
cocultur
differ
concentr
exohasc
pbl
day
prolifer
abil
determin
cfse
dilut
nonstimul
pbl
use
neg
control
stimul
pbl
without
exosom
constitut
posit
control
expect
prolifer
rate
nonstimul
pbl
low
data
shown
maximum
prolifer
rate
reach
stimul
pbl
without
exosom
total
eight
cell
divis
detect
cfse
fluoresc
shown
figur
vitro
stimul
lymphocyt
cultur
presenc
differ
concentr
exohasc
prolifer
rate
proport
decreas
cell
larg
percentag
cell
present
low
number
cell
divis
highest
number
cell
divis
reach
lower
percentag
cell
detail
represent
show
percentag
cell
divis
cycl
provid
figur
repres
histogram
figur
detail
represent
show
percentag
cell
divis
cycl
also
provid
figur
seen
increas
concentr
exosom
arrest
prolifer
eight
gener
seven
moreov
exosom
retain
cell
earlier
divis
cycl
percentag
cell
significantli
higher
presenc
exosom
howev
divis
cycl
significantli
reduc
percentag
cell
higher
dose
exosom
use
first
two
divis
cycl
contain
low
percentag
cell
presenc
absenc
exosom
indic
effect
polyclon
stimul
start
two
divis
cycl
nevertheless
presenc
exosom
still
significantli
retain
cell
fir
two
divis
cycl
although
happen
group
cell
statist
analysi
show
signific
differ
found
differ
divis
cycl
either
cell
final
stimul
index
calcul
cell
frequenc
cfselow
cell
among
unstimul
cell
stimul
index
cell
stimul
respect
howev
pbl
stimul
presenc
exosom
stain
index
significantli
decreas
cell
well
cell
isoform
chemokin
receptor
surfac
marker
commonli
use
identifi
differenti
stage
cell
order
studi
effect
exohasc
lymphocyt
subset
total
stimul
pbl
cultur
presenc
exohasc
two
differ
donor
pbl
day
flow
cytometri
perform
use
commerci
antibodi
quantit
express
normal
refer
control
vitro
stimul
cell
absenc
exohasc
result
show
signific
decreas
cell
cell
posit
control
stimul
pbl
howev
loss
vitro
stimul
pbl
partial
compens
presenc
exohasc
figur
repres
histogram
provid
figur
supplementari
materi
model
propos
lanzavecchia
sallusto
four
differ
stage
defin
within
cell
accord
combin
analysi
express
name
central
memori
least
two
subset
effectormemori
cell
effectormemori
cell
termin
differenti
effectormemori
cell
studi
effect
exohasc
distribut
coexpress
analyz
flow
cytometri
cell
subset
shown
figur
although
percentag
cell
significantli
modifi
presenc
exohasc
signific
decreas
termin
differenti
effectormemori
cell
observ
vitro
stimul
cell
cultur
presenc
exohasc
case
cell
exohasc
reduc
percentag
effectormemori
cell
significantli
increas
percentag
central
memori
cell
proinflammatori
cytokin
secret
immun
cell
certain
condit
activ
direct
correl
secret
level
cell
activ
order
determin
effect
exosom
secretori
respons
cell
pbl
cultur
presenc
absenc
exohasc
day
intracellular
level
determin
cell
subset
result
show
day
percentag
intracellular
reduc
pbl
cultur
exosom
comparison
posit
control
cell
subset
howev
reduct
statist
signific
gate
cell
figur
result
demonstr
exohasc
impair
differenti
phenotyp
lymphocyt
also
secret
hasc
success
use
treatment
numer
diseas
cell
isol
adult
liposuct
tissu
effici
expand
vitro
use
offtheshelf
cellular
product
present
quit
stem
cell
product
market
hasc
current
consid
one
promis
cell
type
therapeut
applic
fulfil
regulatori
requir
hasc
immunomodulatori
properti
directli
mediat
contact
indirectli
mediat
releas
immunosuppress
factor
releas
factor
enhanc
inflammatori
condit
result
suppress
cell
function
prolifer
differenti
cytotox
b
cell
function
nk
cell
cytotox
decreas
matur
activ
dendrit
cell
well
increas
regulatori
cell
among
releas
factor
exosom
msc
consid
promis
candid
novel
cellfre
therapi
present
microvesicl
test
preclin
set
treatment
cardiovascular
diseas
kidney
injuri
graftversushost
diseas
neurolog
diseas
clinic
set
exomsc
test
graftversushost
diseas
patient
experienc
improv
symptom
month
studi
exosom
msc
demonstr
biolog
effect
repair
tissu
damag
immunolog
point
view
exosom
demonstr
immunomodulatori
properti
induc
peripher
toler
modul
immun
respons
work
aim
investig
immunomodulatori
role
enrich
fraction
exohasc
cell
subset
vitro
condit
purpos
cell
vitro
expand
activ
partial
mimic
stimul
antigenpres
cell
immunomodul
assess
measur
prolif
behavior
cell
differenti
toward
memori
lineag
secretori
respons
although
preliminari
studi
result
demonstr
exohasc
significantli
inhibit
prolifer
cell
result
similar
previous
publish
result
use
hasc
cocultur
vitro
activ
pbl
recent
report
demonstr
signal
msc
requir
inhibit
tcell
prolifer
sens
futur
studi
conduct
evalu
antiprolif
activ
exohasc
could
also
relat
activ
togeth
inhibit
cell
prolifer
hypothes
exohasc
may
arrest
cell
differenti
toward
effector
memori
cell
phenotyp
order
confirm
hypothesi
vitro
activ
lymphocyt
cocultur
presenc
exohasc
differenti
profil
cell
monitor
accord
coexpress
molecul
combin
usag
allow
us
identif
differ
cell
subset
cell
subset
naiv
central
memori
effector
memori
termin
differenti
effectormemori
cell
result
evidenc
exohasc
hamper
vitro
differenti
mediat
stimuli
actual
case
cell
exohasc
inhibitori
effect
differenti
toward
termin
differenti
phenotyp
effectormemori
phenotyp
respect
vitro
result
exohasc
show
similar
previou
report
use
msc
vitro
stimul
pbl
lymphocyt
show
reducedmemori
respons
tetanu
toxoid
boost
current
experi
conduct
relev
anim
model
cellmedi
diseas
collageninduc
arthriti
experiment
model
rheumatoid
arthriti
complet
result
give
us
complet
understand
exohasc
therapeut
agent
control
local
cell
respons
final
immunomodulatori
activ
exohasc
determin
measur
product
cell
experi
confirm
similarli
vitro
experi
use
hasc
contact
separ
transwel
product
significantli
reduc
exohasc
consid
crucial
protect
immunemedi
inflammatori
disord
could
assum
exohasc
could
use
ideal
vehicl
local
immunosuppress
moreov
contrast
cell
therapi
viabil
home
implant
individu
cell
compromis
usag
wellcharacter
exohasc
dose
regimen
control
defin
space
time
could
consid
advantag
addit
sever
author
report
suscept
allogen
cell
cell
nk
cell
import
issu
clinic
efficaci
msc
case
exohasc
microvesicl
affect
cellmedi
lysi
advantag
therapeut
effect
import
aspect
discuss
role
mhc
molecul
exosom
previous
describ
et
al
exosom
bone
marrow
dendrit
cell
exodc
induc
regulatori
respons
allograft
toler
present
donormhc
antigen
exodc
posit
mhc
class
mhc
class
ii
costimulatori
molecul
vivo
administr
allogen
exosom
induc
toler
contrari
exodc
exohasc
character
absenc
mhc
class
ii
costimulatori
molecul
regard
mhc
class
hasc
cell
line
contain
low
level
mhc
class
express
molecul
exohasc
still
debat
inde
exocarta
databas
exosom
protein
http
wwwexocartaorg
presenc
hlaa
hlab
hlac
detect
protein
analyz
exomsc
howev
proteom
analysi
exosom
human
embryon
stem
cellderiv
msc
demonstr
presenc
hlaa
molecul
vesicl
hand
consid
human
clinic
trial
use
allogen
hasc
caus
earli
aggress
immunolog
reject
could
assum
allogen
exohasc
nonactiv
hasc
might
similar
consequ
absenc
mhc
class
ii
costimulatori
molecul
exohasc
may
also
indic
vesicl
direct
inhibitori
effect
cell
independ
antigen
present
nevertheless
although
inhibitori
effect
test
allogen
set
use
exohasc
clinic
establish
hasc
futur
experi
conduct
determin
inhibitori
effect
stronger
autolog
cell
limit
studi
evid
paper
pure
focus
vitro
role
exohasc
vitro
activ
cell
subset
futur
experi
confirm
observ
vivo
anim
model
vivo
anim
model
help
us
defin
optim
rout
dose
frequenc
exohasc
administr
summari
paper
provid
better
understand
exohasc
futur
applic
clinic
practic
moreov
term
immunomodul
vitro
result
demonstr
parallel
hasc
exohasc
olga
de
la
rosa
wilfri
daleman
full
time
employe
tigenix
coauthor
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
